UW infectious disease experts are volunteering to help conduct on-site COVID-19 tests and implement CDC prevention guidelines at senior living communities in the Seattle area where positive COVID-19 cases have been detected.
While the U.S. and Europe battle to slow the spread of the novel coronavirus, I can’t help but think about how Africa will cope when it becomes the next epicenter. Based on the three-month-old data that we have about the virus and its spread, guidelines on prevention, containment and mitigation have been set by the World Health Organization (WHO). So far, several African governments have adopted the U.S. and European approach that is centered on lockdowns, social distancing and frequent hand washing with soap and water.
The following is a transcript of an interview with Dr. Christopher Murray that aired Sunday, April 12, 2020, on "Face the Nation."
Newly reported research findings may help in detecting and preventing the spread of COVID19 at independent and assisted living community for senior adults.
One of the valuable lessons from the study at an affected retirement center in Seattle: Health-professionals should not rely solely on symptoms to determine if an older adult should receive a lab test for the coronavirus.
Even before the COVID-19 pandemic, health departments had limited staff, resources and time to support the diverse public health needs of our communities. This system will be further strained as the epidemic grows. We must immediately create a national public health reserve to shore up public health systems.
Things are still getting worse. The US death toll crossed 14,000 on Wednesday, with a record 1,858 deaths reported just on Tuesday. Since the outbreak started, about 425,000 cases have been diagnosed in the US. And researchers say the peak has yet to come.
The Coler Lab at Seattle Children’s Research Institute is using their expertise to support the clinical trial of an experimental coronavirus vaccine funded by National Institute of Allergy and Infectious Diseases (NIAID), part of the U.S. National Institutes of Health. The trial is being conducted at the Kaiser Permanente Washington Health Research Institute in Seattle, part of NIAID’s Infectious Diseases Clinical Research Consortium.
A University of Washington study provides some of the first details of 21 critically ill patients with the coronavirus disease 2019 (COVID-19) in the United States, most of whom were linked to exposures at a nursing home at the center of the country’s COVID-19 outbreak early on in the global crisis.
The benefits of hydroxychloroquine being investigated in multi-site clinical trial launching in April
Researchers are investigating whether hydroxychloroquine – a commonly used anti-malarial and autoimmune drug – can prevent COVID-19.
A multi-site clinical trial, led by the University of Washington Department of Global Health/International Clinical Research Center (ICRC) in collaboration with NYU Grossman School of Medicine, aims to definitively determine whether hydroxychloroquine can prevent transmission in people exposed to the virus.
The COVID-19 crisis has brought a whirlwind of changes that have impacted everyone in our community — including this year’s graduating class of medical students at UW School of Medicine.
In the last few weeks, the students were pulled from their clinical rotations early.
Then, the difficult and unprecedented decision was made to hold the School’s Match Day ceremony online.